Connect Biopharma (NASDAQ:CNTB – Get Free Report) and Organogenesis (NASDAQ:ORGO – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership and valuation.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Connect Biopharma and Organogenesis, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Connect Biopharma | 1 | 0 | 8 | 0 | 2.78 |
| Organogenesis | 1 | 2 | 0 | 0 | 1.67 |
Connect Biopharma presently has a consensus target price of $5.88, indicating a potential upside of 752.81%. Organogenesis has a consensus target price of $4.33, indicating a potential upside of 312.70%. Given Connect Biopharma’s stronger consensus rating and higher possible upside, analysts plainly believe Connect Biopharma is more favorable than Organogenesis.
Insider & Institutional Ownership
Earnings & Valuation
This table compares Connect Biopharma and Organogenesis”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Connect Biopharma | $2.95 million | 14.69 | -$55.48 million | ($1.19) | -0.58 |
| Organogenesis | $564.17 million | 0.24 | $37.03 million | ($1.22) | -0.86 |
Organogenesis has higher revenue and earnings than Connect Biopharma. Organogenesis is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Connect Biopharma has a beta of 0.06, meaning that its share price is 94% less volatile than the S&P 500. Comparatively, Organogenesis has a beta of 1.48, meaning that its share price is 48% more volatile than the S&P 500.
Profitability
This table compares Connect Biopharma and Organogenesis’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Connect Biopharma | N/A | -165.41% | -121.58% |
| Organogenesis | -39.34% | -55.28% | -23.72% |
Summary
Connect Biopharma beats Organogenesis on 8 of the 13 factors compared between the two stocks.
About Connect Biopharma
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory diseases driven by T-cell activity. The company’s research programs target conditions in immunology, including inflammatory bowel disease, atopic dermatitis and other immune-mediated disorders. Its pipeline has included rademikibart, formerly known as CBP-201, an investigational monoclonal antibody designed to block the interleukin-4 receptor alpha pathway, and ropsacitinib, formerly known as CBP-307, an investigational oral TYK2 inhibitor.
About Organogenesis
Organogenesis Holdings Inc. is a biotechnology company that develops, manufactures and commercializes products intended to support tissue regeneration and wound healing. The company serves the advanced wound care and surgical and sports medicine markets, with a focus on therapies that help manage complex wounds and support the repair of damaged tissue. Its product portfolio includes bioengineered skin substitutes and other biologic products, such as Apligraf, Dermagraft, NuShield, Affinity and NuCel.
Receive News & Ratings for Connect Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Connect Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
